ArticleArchives of endocrinology and metabolism2025
Overexpression of PON1 reduces high glucose induced renal tubular epithelial cell injury by activating PPARγ signaling pathway to alleviate diabetes nephropathy.
Article in Archives of endocrinology and metabolism, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Withaferin A, a candidate drug for lupus nephritis, confers renal protection via Pon1‑mediated attenuation of oxidative stress.International journal of molecular medicine · 2026Article
- A dual-action core-shell microneedle system restores mitochondrial function and accelerates healing in diabetic wounds.Journal of nanobiotechnology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo investigate the role of PON1 in diabetic nephropathy and elucidate the underlying mechanisms using a cellular model. MATERIALS AND
methodsA diabetic nephropathy model was established using high glucose-induced HK-2 cells. Potential target genes and signaling pathways were identified through bioinformatics databases, and PON1 expression was manipulated to interfere with these pathways. The effects of different treatments on cell conditions were systematically evaluated.
resultsPON1, the targeted gene in diabetic nephropathy, was significantly downregulated in high glucose-induced cells. The PPARγ signaling pathway was identified as closely associated with PON1, with both PPARα and PPARγ emerging as key regulators within this pathway. We observed significant increases in lactate dehydrogenase activity, malondialdehyde levels, and cell apoptosis, along with notable decreases in superoxide dismutase levels, cell viability, and cell proliferation, in the high glucose-treated group. Additionally, the expression levels of PPARα and PPARγ were also decreased. Overexpression of PON1 (pc-PON1) in the high glucose group mitigated these effects, whereas treatment with the PPARγ antagonist GW9662 reversed the protective changes induced by pc-PON1.
conclusionElevated PON1 levels mitigated oxidative stress and inhibited cell death, thereby promoting cell growth and alleviating diabetic nephropathy through activation of the PPARγ signaling pathway.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.